Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

(Z)-N-[3-(4-Bromo-benzo-yl)-1,3-thia-zolidin-2-yl-idene]cyanamide.

Acta crystallographica. Section E, Structure reports online·2011
Same author

Identification of a novel estrogen receptor beta1 binding partner, inhibitor of differentiation-1, and role of ERbeta1 in human breast cancer cells.

Cancer letters·2009
Same author

Luttinger liquid to Al'tshuler-Aronov transition in disordered, many-channel carbon nanotubes.

ACS nano·2009
Same author

Pathological changes in multiple organs of rats with severe acute pancreatitis treated by baicalin and octreotide.

Hepatobiliary & pancreatic diseases international : HBPD INT·2009
Same author

Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice.

Journal of autoimmunity·2009
Same author

Tailoring optical transmission via the arrangement of compound subwavelength hole arrays.

Optics express·2009

Related Experiment Video

Updated: Sep 11, 2025

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective
06:14

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective

Published on: January 12, 2024

2.0K

Targeted therapy for knee osteoarthritis: From basic to clinics.

Li Chen1, Feng-Lan Huang1, Qi Tang1

  • 1West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.

Medicine
|August 19, 2025
PubMed
Summary

Knee osteoarthritis (KOA) treatments are advancing with novel targeted therapies like biologicals and nanomedicine. This review highlights recent breakthroughs, offering hope for improved patient outcomes and management of this growing public health challenge.

Keywords:
clinical trialsinhibitorsknee osteoarthritisnanocarrierstargeted therapy

More Related Videos

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint
06:06

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint

Published on: July 22, 2021

6.1K
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

1.3K

Related Experiment Videos

Last Updated: Sep 11, 2025

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective
06:14

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective

Published on: January 12, 2024

2.0K
Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint
06:06

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint

Published on: July 22, 2021

6.1K
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

1.3K

Area of Science:

  • Orthopedics
  • Rheumatology
  • Regenerative Medicine

Background:

  • Knee osteoarthritis (KOA) incidence is rising due to aging populations and lifestyle factors, posing a significant public health challenge.
  • Current treatments for KOA inadequately address its complex pathophysiology and diverse clinical manifestations, highlighting an unmet medical need.
  • Effective KOA management is crucial for improving patients' quality of life.

Purpose of the Study:

  • To review and summarize recent advancements in targeted therapeutic interventions for knee osteoarthritis.
  • To analyze the latest breakthroughs in pharmaceutical therapies and clinical data for KOA treatment.
  • To provide a valuable resource for clinicians and researchers seeking effective KOA management strategies.

Main Methods:

  • Comprehensive review of current literature on targeted therapies for knee osteoarthritis.
  • Analysis of clinical trial data for novel KOA treatments, including biologicals, nanomedicine, gene therapy, and cell therapy.
  • Examination of advancements in drug nanocarriers and delivery systems for enhanced therapeutic efficacy.

Main Results:

  • Numerous novel targeted therapies, including small-molecule inhibitors, monoclonal antibodies, nanocarrier-based therapy, gene therapy, and cytotherapy, are in clinical trials for KOA.
  • Advancements in nanocarrier technology show promise for improving the efficacy of therapeutic agents in KOA treatment.
  • The review consolidates information on emerging treatments, offering insights into their potential clinical applications.

Conclusions:

  • Targeted therapies represent a promising frontier for managing knee osteoarthritis, addressing the limitations of current treatment options.
  • Continued research and clinical trials are essential to translate these novel therapeutic approaches into effective clinical practice for KOA.
  • These advancements offer hope for better disease control and improved quality of life for individuals suffering from knee osteoarthritis.